Institutional shares held 2.89 Million
0 calls
0 puts
Total value of holdings $21.1M
$0 calls
$0 puts
Market Cap $700M
94,362,304 Shares Out.
Institutional ownership 3.06%
# of Institutions 7


Latest Institutional Activity in ATRA

Top Purchases

Q4 2024
Alexis Investment Partners, LLC Shares Held: 28 ($208)
Q2 2024
Ever Source Wealth Advisors, LLC Shares Held: 35 ($260)
Q1 2024
Bank Of America Corp Shares Held: 6.58M ($48.8M)
Q1 2024
Citadel Advisors LLC Shares Held: 6.51M ($48.3M)
Q1 2024
Price T Rowe Associates Inc Shares Held: 4.96M ($36.8M)

Top Sells

Q2 2024
Boxer Capital, LLC Shares Held: 166K ($1.23M)
Q2 2024
Cwm, LLC Shares Held: 542 ($4.02K)
Q1 2024
Ubs Group Ag Shares Held: 106K ($790K)
Q1 2024
Millennium Management LLC Shares Held: 361K ($2.68M)
Q1 2024
Vanguard Group Inc Shares Held: 5.01M ($37.2M)

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.


Insider Transactions at ATRA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
79.1K Shares
From 2 Insiders
Grant, award, or other acquisition 79.1K shares
Sell / Disposition
229K Shares
From 5 Insiders
Open market or private sale 229K shares

Track Institutional and Insider Activities on ATRA

Follow Atara Biotherapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATRA shares.

Notify only if
Any

Insider Trading

Get notified when an Atara Biotherapeutics, Inc. insider buys or sells ATRA shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Atara Biotherapeutics, Inc.

Track Activities on ATRA